| Patient | Lili Boulanger |
|---|---|
| Date of birth | 1893-08-21 |
| Identifiers | MRN HR-ET025-SYN-TD; SSN (made up) 000-25-7731 |
| Document date | 1915-08-03 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review on maintenance risankizumab. [S]
Ms. Boulanger is six months into risankizumab, with two maintenance doses given, the second at home, and the next due in two weeks. She has one or two formed stools a day, no pain, and no extra-intestinal symptoms (Harvey-Bradshaw Index 1). She has regained 5.6 kg since diagnosis. She is composing a new choral work. She asked about having children one day and how her treatment would affect a pregnancy. [S]
| Element | Detail |
|---|---|
| Interval change | Two maintenance doses; no flares or infections |
| Activity | Harvey-Bradshaw Index 1 |
| Weight | 50.6 kg, BMI 19.8 |
| Question | Pregnancy in the future |
| Work | Composing a new choral work |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue |
| Gastrointestinal | Negative | One or two formed stools a day |
| Eyes | Negative | No eye pain or redness |
| Musculoskeletal | Negative | No joint pain |
| Genitourinary | Negative | Regular periods |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 1914-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 1915-02-02 to 1915-04-26 | completed | S |
| Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 | One injection every 8 weeks | Subcutaneous route | 1915-04-27 | active | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 1915-02-02 to 1915-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1915-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1915-08-03 | Body height | 160 | cm | S |
| 1915-08-03 | Body weight | 50.6 | kg | S |
| 1915-08-03 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1915-08-03 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1915-08-03 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1915-08-03 | Heart rate | 72 | /min | S |
| 1915-08-03 | Respiratory rate | 14 | /min | S |
| 1915-08-03 | Body temperature | 36.6 | Cel | S |
| 1915-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1915-08-03 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 1915-08-03 | Ferritin [Mass/volume] in Serum or Plasma | 72 | ng/mL | 15-150 ng/mL | Normal | S |
| 1915-08-03 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 | pg/mL | 200-900 pg/mL | Normal | S |
| 1915-08-03 | C reactive protein [Mass/volume] in Serum or Plasma | 2 | mg/L | <=5 mg/L | Normal | S |
| 1915-08-03 | Calprotectin [Mass/mass] in Stool | 42 | ug/g | <=50 ug/g | Normal | S |
| 1915-08-03 | Albumin [Mass/volume] in Serum or Plasma | 4.3 | g/dL | 3.5-5 g/dL | Normal | S |
| 1915-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1915-08-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; BMI 19.8 |
| Mouth | No ulcers |
| Abdomen | Soft, non-tender; no mass |
| Skin | No erythema nodosum; injection sites clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | resolved | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
| Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | A08.11 | S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 1: remission |
| Laboratory | CRP | Every visit | Completed today | 2 mg/L |
| Laboratory | Fecal calprotectin | About six months after starting treatment, then every 3 to 6 months | Completed today | 42 ug/g, normal: biochemical remission |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Ordered | Booked in about two months |
| Laboratory | Hemoglobin, ferritin, and vitamin B12 | Every 6 to 12 months; B12 yearly with ileal disease | Completed today | Hemoglobin 13.1 g/dL, ferritin 72, vitamin B12 340 pg/mL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 4.3 g/dL; weight 50.6 kg |
| Laboratory | Liver enzymes on maintenance risankizumab | Routine after induction | Not indicated | Induction monitoring was completed and normal; no symptoms |
| Survey | Depression screen (PHQ-9) | At least yearly | Completed today | PHQ-9 3 |
| Self-management | Pregnancy planning and contraception | At least yearly in women of reproductive age | Completed today | Counseled; folic acid before conception; preconception review |
| Medication safety | Infection review and vaccines | Every visit | Completed today | No infections since April; influenza vaccine due in the autumn |
Goal progress:
Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;23:S1-S60 (2025)
Follow-up: Ileocolonoscopy in about two months. Adult preventive visit in the autumn. Next scheduled visit 1915-10-19: adult preventive visit. [S]